$ATIP
ATI Physical Therapy, Inc. Stock $atip

$atip Overview Financials Valuation SEC Filings Company Website

2022 Q2 Form 10-Q Financial Statement

#000181584922000009 Filed on May 10, 2022

Income Statement

Concept	2022 Q2	2022 Q1	2021 Q4
Revenue	$163.3M	$153.8M	$155.8M
YoY Change	-0.45%	3.19%	-73.7%
Cost Of Revenue	$140.0M	$139.0M	$135.9M
YoY Change	-43.76%	12.17%	-71.25%
Gross Profit	$23.28M	$14.79M	$19.88M
YoY Change	-63.71%	-41.1%	-83.38%
Gross Profit Margin	14.26%	9.62%	12.77%
Selling, General & Admin	$32.06M	$30.02M	$29.90M
YoY Change	21.5%	21.43%	-74.94%
% of Gross Profit	137.72%	202.97%	150.36%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$10.26M	$10.11M	$10.00M
YoY Change	13.32%	5.11%	-74.8%
% of Gross Profit	44.06%	68.35%	50.32%
Operating Expenses	$35.31M	$30.02M	$29.90M
YoY Change	33.81%	21.43%	-74.94%
Operating Profit	-$12.03M	-$176.1M	-$12.11M
YoY Change	-97.29%	2495.11%	-3680.36%
Interest Expense	-$11.38M	-$8.656M	-$7.215M
YoY Change	-72.78%	-59.54%	-91.83%
% of Operating Profit
Other Income/Expense, Net	$2.475M	-$2.781M	$15.64M
YoY Change	-143.99%	1717.65%	-82.82%
Pretax Income	-$148.8M	-$161.5M	-$3.691M
YoY Change	-69.47%	470.02%	-222.79%
Income Tax	-$13.03M	-$23.30M	-$5.381M
% Of Pretax Income
Net Earnings	-$135.5M	-$137.8M	$821.0K
YoY Change	-68.87%	620.19%	-119.87%
Net Earnings / Revenue	-83.01%	-89.55%	0.53%
Basic Earnings Per Share	-$34.49	-$0.70	$0.00
Diluted Earnings Per Share	-$664.9K	-$0.70	$0.00
COMMON SHARES
Basic Shares Outstanding	206.8M shares	200.0M shares	197.3M shares
Diluted Shares Outstanding	4.077M shares	200.0M shares	197.4M shares

Balance Sheet

Concept	2022 Q2	2022 Q1	2021 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$79.68M	$94.80M	$48.62M
YoY Change	-12.02%	58225.85%	-65.79%
Cash & Equivalents	$79.68M	$94.80M	$48.62M
Short-Term Investments
Other Short-Term Assets	$27.68M	$6.658M	$3.204M
YoY Change	267.01%	1815.2%	47.79%
Inventory
Prepaid Expenses		$8.706M	$9.303M
Receivables	$83.19M	$87.81M	$82.46M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$190.5M	$198.0M	$143.6M
YoY Change	2.61%	38704.94%	-39.89%
LONG-TERM ASSETS
Property, Plant & Equipment	$380.8M	$136.8M	$139.7M
YoY Change	184.22%		1.86%
Goodwill		$492.2M	$608.8M
YoY Change		-62.14%	-54.23%
Intangibles		$372.1M	$411.7M
YoY Change			-36.11%
Long-Term Investments
YoY Change
Other Assets	$2.013M	$2.811M	$2.233M
YoY Change	7.59%		32.52%
Total Long-Term Assets	$1.119B	$1.259B	$1.419B
YoY Change	-41.55%	265.0%	-40.16%
TOTAL ASSETS
Total Short-Term Assets	$190.5M	$198.0M	$143.6M
Total Long-Term Assets	$1.119B	$1.259B	$1.419B
Total Assets	$1.310B	$1.457B	$1.563B
YoY Change	-37.64%	321.76%	-40.14%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$14.37M	$12.26M	$15.15M
YoY Change	17.25%	122.67%	24.68%
Accrued Expenses	$109.9M	$102.6M	$105.1M
YoY Change	8.33%	208022.47%	-8.7%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$0.00	$0.00	$8.167M
YoY Change	-100.0%		0.0%
Total Short-Term Liabilities	$131.9M	$122.3M	$137.3M
YoY Change	2.31%	2100.9%	-4.23%
LONG-TERM LIABILITIES
Long-Term Debt	$478.5M	$477.8M	$543.8M
YoY Change	-12.48%		-45.15%
Other Long-Term Liabilities	$260.8M	$2.348M	$2.301M
YoY Change	3363.03%	-92.86%	-87.61%
Total Long-Term Liabilities	$739.3M	$480.2M	$546.1M
YoY Change	33.37%	1360.65%	-45.93%
TOTAL LIABILITIES
Total Short-Term Liabilities	$131.9M	$122.3M	$137.3M
Total Long-Term Liabilities	$739.3M	$480.2M	$546.1M
Total Liabilities	$908.1M	$918.7M	$1.051B
YoY Change	-28.19%	2290.54%	-38.5%
SHAREHOLDERS EQUITY
Retained Earnings		-$984.9M	-$847.1M
YoY Change		16854.9%	1131.22%
Common Stock		$20.00K	$20.00K
YoY Change			53.85%
Preferred Stock
YoY Change
Treasury Stock (at cost)		$100.0K	$95.00K
YoY Change
Treasury Stock Shares		40.00K shares	30.00K shares
Shareholders Equity	$401.5M	$392.1M	$504.4M
YoY Change
Total Liabilities & Shareholders Equity	$1.310B	$1.457B	$1.563B
YoY Change	-37.64%	321.76%	-40.14%

Cashflow Statement

Concept	2022 Q2	2022 Q1	2021 Q4
OPERATING ACTIVITIES
Net Income	-$135.5M	-$137.8M	$821.0K
YoY Change	-68.87%	620.19%	-119.87%
Depreciation, Depletion And Amortization	$10.26M	$10.11M	$10.00M
YoY Change	13.32%	5.11%	-74.8%
Cash From Operating Activities	-$6.006M	-$26.73M	-$3.437M
YoY Change	-76.84%	-11.11%	-102.47%
INVESTING ACTIVITIES
Capital Expenditures	-$9.069M	$8.772M	-$12.89M
YoY Change	-52.79%	4.73%	-41.76%
Acquisitions
YoY Change
Other Investing Activities	$109.0K	$114.0K	$1.706M
YoY Change	-54.6%	308.6%	-99.51%
Cash From Investing Activities	-$8.960M	-$8.658M	-$11.19M
YoY Change	-52.77%	-1.19%	-103.46%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net		$555.0M
YoY Change		27081.59%
Cash From Financing Activities	-151.0K	$81.57M	-2.853M
YoY Change	-97.26%	-1552.2%	-99.21%
NET CHANGE
Cash From Operating Activities	-6.006M	-$26.73M	-3.437M
Cash From Investing Activities	-8.960M	-$8.658M	-11.19M
Cash From Financing Activities	-151.0K	$81.57M	-2.853M
Net Change In Cash	-15.12M	$46.18M	-17.48M
YoY Change	-70.01%	-203.89%	-117.07%
FREE CASH FLOW
Cash From Operating Activities	-$6.006M	-$26.73M	-$3.437M
Capital Expenditures	-$9.069M	$8.772M	-$12.89M
Free Cash Flow	$3.063M	-$35.50M	$9.455M
YoY Change	-145.59%	-7.66%	-94.13%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q1	dei	Amendment Flag AmendmentFlag	false
CY2022Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001815849
CY2022Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022Q1	dei	Entity Small Business EntitySmallBusiness	false
CY2022Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022Q1	dei	Entity Shell Company EntityShellCompany	false
CY2022Q1	dei	Document Type DocumentType	10-Q
CY2022Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2022Q1	dei	Document Period End Date DocumentPeriodEndDate	2022-03-31
CY2022Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2022Q1	dei	Entity File Number EntityFileNumber	001-39439
CY2022Q1	dei	Entity Registrant Name EntityRegistrantName	ATI Physical Therapy, Inc.
CY2022Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2022Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	85-1408039
CY2022Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	790 Remington Boulevard
CY2022Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Bolingbrook
CY2022Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	IL
CY2022Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	60440
CY2022Q1	dei	City Area Code CityAreaCode	630
CY2022Q1	dei	Local Phone Number LocalPhoneNumber	296-2223
CY2022Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022Q1	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2022Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	206825028	shares
CY2022Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	94797000	USD
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	48616000	USD
CY2022Q1	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	51519000	USD
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	53533000	USD
CY2022Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	87809000	USD
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	82455000	USD
CY2022Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	8706000	USD
CY2021Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	9303000	USD
CY2022Q1	us-gaap	Other Assets Current OtherAssetsCurrent	6658000	USD
CY2021Q4	us-gaap	Other Assets Current OtherAssetsCurrent	3204000	USD
CY2022Q1	us-gaap	Assets Current AssetsCurrent	197970000	USD
CY2021Q4	us-gaap	Assets Current AssetsCurrent	143578000	USD
CY2022Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	136776000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	139730000	USD
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	255372000	USD
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	256646000	USD
CY2022Q1	us-gaap	Goodwill Goodwill	492240000	USD
CY2021Q4	us-gaap	Goodwill Goodwill	608811000	USD
CY2022Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	372090000	USD
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	411696000	USD
CY2022Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2811000	USD
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2233000	USD
CY2022Q1	us-gaap	Assets Assets	1457259000	USD
CY2021Q4	us-gaap	Assets Assets	1562694000	USD
CY2022Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	12264000	USD
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	15146000	USD
CY2022Q1	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	59391000	USD
CY2021Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	64584000	USD
CY2022Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	50651000	USD
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	49433000	USD
CY2022Q1	us-gaap	Long Term Debt Current LongTermDebtCurrent	0	USD
CY2021Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	8167000	USD
CY2022Q1	us-gaap	Liabilities Current LiabilitiesCurrent	122306000	USD
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	137330000	USD
CY2022Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	477817000	USD
CY2021Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	543799000	USD
CY2022Q1	ati	Warrant Liability Noncurrent WarrantLiabilityNoncurrent	2664000	USD
CY2021Q4	ati	Warrant Liability Noncurrent WarrantLiabilityNoncurrent	4341000	USD
CY2022Q1	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	21026000	USD
CY2021Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	45360000	USD
CY2022Q1	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	44178000	USD
CY2021Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	67459000	USD
CY2022Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	248354000	USD
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	250597000	USD
CY2022Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2348000	USD
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2301000	USD
CY2022Q1	us-gaap	Liabilities Liabilities	918693000	USD
CY2021Q4	us-gaap	Liabilities Liabilities	1051187000	USD
CY2022Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2021Q4	ati	Temporary Equity Par Value Per Share TemporaryEquityParValuePerShare	0.0001
CY2022Q1	ati	Temporary Equity Par Value Per Share TemporaryEquityParValuePerShare	0.0001
CY2021Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	1000000	shares
CY2022Q1	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	1000000	shares
CY2022Q1	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	200000	shares
CY2022Q1	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	200000	shares
CY2021Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	0	shares
CY2021Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	0	shares
CY2022Q1	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	140340000	USD
CY2021Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	0	USD
CY2022Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	470000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	470000000	shares
CY2022Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	207400000	shares
CY2022Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	197500000	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	207400000	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	197400000	shares
CY2022Q1	us-gaap	Common Stock Value CommonStockValue	20000	USD
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	20000	USD
CY2022Q1	us-gaap	Treasury Stock Shares TreasuryStockShares	40000.00	shares
CY2021Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	30000.00	shares
CY2022Q1	us-gaap	Treasury Stock Value TreasuryStockValue	117000	USD
CY2021Q4	us-gaap	Treasury Stock Value TreasuryStockValue	95000	USD
CY2022Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1373282000	USD
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1351597000	USD
CY2022Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	3780000	USD
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	28000	USD
CY2022Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-984882000	USD
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-847132000	USD
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	392083000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	504418000	USD
CY2022Q1	us-gaap	Minority Interest MinorityInterest	6143000	USD
CY2021Q4	us-gaap	Minority Interest MinorityInterest	7089000	USD
CY2022Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	398226000	USD
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	511507000	USD
CY2022Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1457259000	USD
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1562694000	USD
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	153822000	USD
CY2021Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	149062000	USD
CY2022Q1	us-gaap	Labor And Related Expense LaborAndRelatedExpense	87415000	USD
CY2021Q1	us-gaap	Labor And Related Expense LaborAndRelatedExpense	80654000	USD
CY2022Q1	ati	Rent Clinic Supplied Contract Labor And Other Operating Expenses RentClinicSuppliedContractLaborAndOtherOperatingExpenses	51615000	USD
CY2021Q1	ati	Rent Clinic Supplied Contract Labor And Other Operating Expenses RentClinicSuppliedContractLaborAndOtherOperatingExpenses	43296000	USD
CY2021Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	USD
CY2022Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	5105000	USD
CY2021Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	7171000	USD
CY2022Q1	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	144135000	USD
CY2021Q1	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	131121000	USD
CY2022Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	30024000	USD
CY2021Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	24726000	USD
CY2022Q1	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	155741000	USD
CY2021Q1	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	0	USD
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-176078000	USD
CY2021Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-6785000	USD
CY2022Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-1677000	USD
CY2022Q1	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	24334000	USD
CY2021Q1	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	0	USD
CY2022Q1	ati	Interest Income Expense Nonoperating Net Excluding Redeemable Preferred Stock InterestIncomeExpenseNonoperatingNetExcludingRedeemablePreferredStock	-8656000	USD
CY2021Q1	ati	Interest Income Expense Nonoperating Net Excluding Redeemable Preferred Stock InterestIncomeExpenseNonoperatingNetExcludingRedeemablePreferredStock	-16087000	USD
CY2022Q1	ati	Interest Expense On Redeemable Preferred Stock InterestExpenseOnRedeemablePreferredStock	0	USD
CY2021Q1	ati	Interest Expense On Redeemable Preferred Stock InterestExpenseOnRedeemablePreferredStock	5308000	USD
CY2022Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-2781000	USD
CY2021Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-153000	USD
CY2022Q1	us-gaap	Income Loss Including Portion Attributable To Noncontrolling Interest IncomeLossIncludingPortionAttributableToNoncontrollingInterest	-161504000	USD
CY2021Q1	us-gaap	Income Loss Including Portion Attributable To Noncontrolling Interest IncomeLossIncludingPortionAttributableToNoncontrollingInterest	-28333000	USD
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-23281000	USD
CY2021Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-10515000	USD
CY2022Q1	us-gaap	Profit Loss ProfitLoss	-138223000	USD
CY2021Q1	us-gaap	Profit Loss ProfitLoss	-17818000	USD
CY2022Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-473000	USD
CY2021Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	1309000	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-137750000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-19127000	USD
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.70
CY2021Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.15
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.70
CY2021Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.15
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	199971000	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	199971000	shares
CY2021Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	128286000	shares
CY2021Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	128286000	shares
CY2022Q1	us-gaap	Profit Loss ProfitLoss	-138223000	USD
CY2021Q1	us-gaap	Profit Loss ProfitLoss	-17818000	USD
CY2022Q1	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax	3752000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax	561000	USD
CY2022Q1	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-134471000	USD
CY2021Q1	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-17257000	USD
CY2022Q1	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-473000	USD
CY2021Q1	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	1309000	USD
CY2022Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-133998000	USD
CY2021Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-18566000	USD
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	511507000	USD
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	19725000	USD
CY2022Q1	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	22000	USD
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1960000	USD
CY2022Q1	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax	3752000	USD
CY2022Q1	us-gaap	Minority Interest Decrease From Distributions To Noncontrolling Interest Holders MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders	473000	USD
CY2022Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-473000	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-137750000	USD
CY2022Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	398226000	USD
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	901117000	USD
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	504000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax	561000	USD
CY2021Q1	us-gaap	Minority Interest Decrease From Distributions To Noncontrolling Interest Holders MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders	3575000	USD
CY2021Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	1309000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-19127000	USD
CY2021Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	880789000	USD
CY2022Q1	us-gaap	Profit Loss ProfitLoss	-138223000	USD
CY2021Q1	us-gaap	Profit Loss ProfitLoss	-17818000	USD
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	1960000	USD
CY2021Q1	us-gaap	Share Based Compensation ShareBasedCompensation	504000	USD
CY2022Q1	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	155741000	USD
CY2021Q1	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	0	USD
CY2022Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	10111000	USD
CY2021Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	9619000	USD
CY2022Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	5105000	USD
CY2021Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	7171000	USD
CY2022Q1	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-23281000	USD
CY2021Q1	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-10515000	USD
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	11807000	USD
CY2021Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	11055000	USD
CY2022Q1	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	660000	USD
CY2021Q1	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	1045000	USD
CY2022Q1	ati	Increase Decrease In Accrued Interest On Redeemable Preferred Stock IncreaseDecreaseInAccruedInterestOnRedeemablePreferredStock	0	USD
CY2021Q1	ati	Increase Decrease In Accrued Interest On Redeemable Preferred Stock IncreaseDecreaseInAccruedInterestOnRedeemablePreferredStock	5308000	USD
CY2022Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-1677000	USD
CY2021Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	USD
CY2022Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-2809000	USD
CY2021Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2022Q1	us-gaap	Gain Loss On Sales Of Assets And Asset Impairment Charges GainLossOnSalesOfAssetsAndAssetImpairmentCharges	219000	USD
CY2021Q1	us-gaap	Gain Loss On Sales Of Assets And Asset Impairment Charges GainLossOnSalesOfAssetsAndAssetImpairmentCharges	-221000	USD
CY2022Q1	ati	Change In Fair Value Of Contingent Common Share Liability ChangeInFairValueOfContingentCommonShareLiability	-24334000	USD
CY2021Q1	ati	Change In Fair Value Of Contingent Common Share Liability ChangeInFairValueOfContingentCommonShareLiability	0	USD
CY2022Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	10459000	USD
CY2021Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	11148000	USD
CY2022Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-588000	USD
CY2021Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	5265000	USD
CY2022Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-14000	USD
CY2021Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	112000	USD
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-928000	USD
CY2021Q1	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	1060000	USD
CY2022Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-544000	USD
CY2021Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-5686000	USD
CY2022Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-11555000	USD
CY2021Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-15984000	USD
CY2022Q1	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-37000	USD
CY2021Q1	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	473000	USD
CY2022Q1	ati	Increase Decrease In Medicare Accelerated And Advance Payment Funds IncreaseDecreaseInMedicareAcceleratedAndAdvancePaymentFunds	-4269000	USD
CY2021Q1	ati	Increase Decrease In Medicare Accelerated And Advance Payment Funds IncreaseDecreaseInMedicareAcceleratedAndAdvancePaymentFunds	0	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-26731000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-30072000	USD
CY2022Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	8772000	USD
CY2021Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	8376000	USD
CY2022Q1	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	0	USD
CY2021Q1	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	650000	USD
CY2022Q1	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	114000	USD
CY2021Q1	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	16000	USD
CY2022Q1	us-gaap	Proceeds From Divestiture Of Businesses ProceedsFromDivestitureOfBusinesses	0	USD
CY2021Q1	us-gaap	Proceeds From Divestiture Of Businesses ProceedsFromDivestitureOfBusinesses	248000	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-8658000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-8762000	USD
CY2022Q1	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	500000000	USD
CY2021Q1	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	0	USD
CY2022Q1	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	12952000	USD
CY2021Q1	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	USD
CY2022Q1	ati	Payment Of Debt Issuance Discount PaymentOfDebtIssuanceDiscount	10000000	USD
CY2021Q1	ati	Payment Of Debt Issuance Discount PaymentOfDebtIssuanceDiscount	0	USD
CY2022Q1	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	555048000	USD
CY2021Q1	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	2042000	USD
CY2022Q1	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	144667000	USD
CY2021Q1	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	0	USD
CY2022Q1	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	20333000	USD
CY2021Q1	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	0	USD
CY2021Q1	ati	Payment Of Stock Issuance Costs And Issuance Discounts PaymentOfStockIssuanceCostsAndIssuanceDiscounts	0	USD
CY2022Q1	ati	Payment Of Stock Issuance Costs And Issuance Discounts PaymentOfStockIssuanceCostsAndIssuanceDiscounts	4935000	USD
CY2022Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	22000	USD
CY2021Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	0	USD
CY2022Q1	us-gaap	Payments To Minority Shareholders PaymentsToMinorityShareholders	473000	USD
CY2021Q1	us-gaap	Payments To Minority Shareholders PaymentsToMinorityShareholders	3575000	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	81570000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-5617000	USD
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	46181000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-44451000	USD
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	48616000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	142128000	USD
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	94797000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	97677000	USD
CY2022Q1	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	-3752000	USD
CY2021Q1	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	-561000	USD
CY2022Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	2223000	USD
CY2021Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	2161000	USD
CY2022Q1	us-gaap	Interest Paid Net InterestPaidNet	3932000	USD
CY2021Q1	us-gaap	Interest Paid Net InterestPaidNet	14990000	USD
CY2022Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	35000	USD
CY2021Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	1000	USD
CY2022Q1	us-gaap	Nature Of Operations NatureOfOperations	Overview of the Company<div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ATI Physical Therapy, Inc., together with its subsidiaries (herein referred to as “we,” “the Company,” “ATI Physical Therapy” and “ATI”), is a nationally recognized healthcare company, specializing in outpatient rehabilitation and adjacent healthcare services. The Company provides outpatient physical therapy services under the name ATI Physical Therapy and, as of March 31, 2022, had 922 clinics (as well as 20 clinics under management service agreements) located in 25 states. The Company offers a variety of services within its clinics, including physical therapy to treat spine, shoulder, knee and neck injuries or pain; work injury rehabilitation services, including work conditioning and work hardening; hand therapy; and other specialized treatment services. The Company’s direct and indirect wholly-owned subsidiaries include, but are not limited to, Wilco Holdco, Inc., ATI Holdings Acquisition, Inc. and ATI Holdings, LLC.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 16, 2021 (the “Closing Date”), a Business Combination transaction (the “Business Combination”) was finalized pursuant to the Agreement and Plan of Merger ("Merger Agreement"), dated February 21, 2021 between the operating company, Wilco Holdco, Inc. (“Wilco Holdco”), and Fortress Value Acquisition Corp. II (herein referred to as "FAII" and "FVAC"), a special purpose acquisition company. In connection with the closing of the Business Combination, the Company changed its name from Fortress Value Acquisition Corp. II to ATI Physical Therapy, Inc. The Company’s common stock is listed on the New York Stock Exchange ("NYSE") under the symbol “ATIP.”</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Business Combination was accounted for as a reverse recapitalization in accordance with U.S. generally accepted accounting principles ("GAAP"). Under </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">this method of accounting, FAII is treated as the acquired company and Wilco Holdco is treated as the acquirer for financial statement reporting and accounting purposes. As a result, the historical operations of Wilco Holdco are deemed to be those of the Company. Therefore, the financial statements included in this report reflect (i) the historical operating results of Wilco Holdco prior to the Business Combination; (ii) the combined results of FAII and Wilco Holdco following the Business Combination on June 16, 2021; (iii) the assets and liabilities of Wilco Holdco at their historical cost; and (iv) the Company’s equity structure for all periods presented. The recapitalization of the number of shares of common stock attributable to the Business Combination is reflected retroactively to the earliest period presented and will be utilized for calculating earnings per share in all prior periods presented. No step-up basis of intangible assets or goodwill was recorded in the Business Combination consistent with the treatment of the transaction as a reverse recapitalization of Wilco Holdco, Inc. Refer to Note 3 - </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations and Divestiture</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for additional information.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impact of COVID-19 and CARES Act</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The coronavirus ("COVID-19") pandemic in the United States resulted in changes to our operating environment. We continue to closely monitor the impact of COVID-19 on all aspects of our business, and our priorities remain protecting the health and safety of employees and patients, maximizing the availability of services to satisfy patient needs and improving the operational and financial stability of our business. While we expect the disruption caused by COVID-19 and resulting impacts to diminish over time, we cannot predict the length of such impacts, and if such impacts continue for an extended period, it could have a continued effect on the Company’s results of operations, financial condition and cash flows, which could be material.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”) was signed into law providing reimbursement, grants, waivers and other funds to assist health care providers during the COVID-19 pandemic. The Company has realized benefits under the CARES Act including, but not limited to, the following: </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The Company applied for and obtained approval to receive $26.7 million of Medicare Accelerated and Advance Payment Program ("MAAPP") funds during the quarter ended June 30, 2020. During the three months ended March 31, 2022, the Company applied $4.3 million in MAAPP funds against the outstanding liability. Because the Company has not yet met all required performance obligations or performed the services related to the remaining funds, as of March 31, 2022 and December 31, 2021, $8.0 million and $12.3 million of the funds are recorded in accrued expenses and other liabilities, respectively.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The Company elected to defer depositing the employer portion of Social Security taxes for payments due from March 27, 2020 through December 31, 2020, interest-free and penalty-free. Related to these payments, as of March 31, 2022 and December 31, 2021, $5.9 million is included in accrued expenses and other liabilities.</span></div>
CY2022Q1	us-gaap	Number Of Stores NumberOfStores	922	clinic
CY2022Q1	ati	Number Of Stores Under Management Service Agreements NumberOfStoresUnderManagementServiceAgreements	20	clinic
CY2022Q1	us-gaap	Number Of States In Which Entity Operates NumberOfStatesInWhichEntityOperates	25	state
CY2022Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2022Q1	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment
CY2021Q2	ati	Recapitalization Exchange Ratio RecapitalizationExchangeRatio	136.7
CY2021Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	207300000	shares
CY2021Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	196600000	shares
CY2021Q2	us-gaap	Stock Issued During Period Shares Acquisitions StockIssuedDuringPeriodSharesAcquisitions	34137000	shares
CY2021Q2	ati	Stock Converted Reverse Recapitalization Shares StockConvertedReverseRecapitalizationShares	130300000	shares
CY2021Q2	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	30000000	shares
CY2021Q2	us-gaap	Stock Issued During Period Shares Conversion Of Convertible Securities StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities	12845000	shares
CY2021Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	207282000	shares
CY2021Q2	ati	Common Stock Shares Issued Vesting Shares CommonStockSharesIssuedVestingShares	8625000	shares
CY2021Q2	ati	Common Stock Shares Issued Restricted CommonStockSharesIssuedRestricted	2014000	shares
CY2021Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	196643000	shares
CY2021Q2	ati	Cash Acquired Through Reverse Recapitalization CashAcquiredThroughReverseRecapitalization	345036000	USD
CY2021	ati	Adjustments To Additional Paid In Capital Recapitalization Transaction Costs AdjustmentsToAdditionalPaidInCapitalRecapitalizationTransactionCosts	19200000	USD
CY2021Q2	us-gaap	Payments For Repurchase Of Equity PaymentsForRepurchaseOfEquity	89877000	USD
CY2021Q2	ati	Payments Of Reverse Recapitalization Transaction Costs PaymentsOfReverseRecapitalizationTransactionCosts	25821000	USD
CY2021Q2	ati	Proceeds From Reverse Recapitalization ProceedsFromReverseRecapitalization	229338000	USD
CY2021Q2	ati	Reverse Recapitalization Transaction Cost Offset Against Proceeds ReverseRecapitalizationTransactionCostOffsetAgainstProceeds	19233000	USD
CY2021Q2	ati	Proceeds From Reverse Recapitalization Transaction Net Of Transaction Cost ProceedsFromReverseRecapitalizationTransactionNetOfTransactionCost	210105000	USD
CY2021Q2	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	300000000	USD
CY2021Q2	us-gaap	Payments Of Dividends Preferred Stock And Preference Stock PaymentsOfDividendsPreferredStockAndPreferenceStock	59000000	USD
CY2021	ati	Reverse Recapitalization Transaction Cost ReverseRecapitalizationTransactionCost	5543000	USD
CY2021	ati	Net Increase Decrease In Cash Related To Reverse Recapitalization NetIncreaseDecreaseInCashRelatedToReverseRecapitalization	-2473000	USD
CY2021	ati	Reverse Recapitalization Transaction Cost ReverseRecapitalizationTransactionCost	5500000	USD
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	153822000	USD
CY2021Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	149062000	USD
CY2021Q4	us-gaap	Goodwill Goodwill	608811000	USD
CY2022Q1	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	116335000	USD
CY2022Q1	us-gaap	Goodwill Purchase Accounting Adjustments GoodwillPurchaseAccountingAdjustments	236000	USD
CY2022Q1	us-gaap	Goodwill Goodwill	492240000	USD
CY2021Q4	us-gaap	Goodwill Impaired Accumulated Impairment Loss GoodwillImpairedAccumulatedImpairmentLoss	726800000	USD
CY2022Q1	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	116300000	USD
CY2022Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	372090000	USD
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	411696000	USD
CY2022Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	341864000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	336135000	USD
CY2022Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	205088000	USD
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	196405000	USD
CY2022Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	136776000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	139730000	USD
CY2022Q1	us-gaap	Depreciation Depreciation	9921000	USD
CY2021Q1	us-gaap	Depreciation Depreciation	9564000	USD
CY2022Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	17174000	USD
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	27257000	USD
CY2022Q1	ati	Medicare Accelerated And Advance Payment Funds And Deferred Employer Social Security Tax Cares Act Current MedicareAcceleratedAndAdvancePaymentFundsAndDeferredEmployerSocialSecurityTaxCARESActCurrent	13910000	USD
CY2021Q4	ati	Medicare Accelerated And Advance Payment Funds And Deferred Employer Social Security Tax Cares Act Current MedicareAcceleratedAndAdvancePaymentFundsAndDeferredEmployerSocialSecurityTaxCARESActCurrent	18179000	USD
CY2022Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	8993000	USD
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	5649000	USD
CY2022Q1	us-gaap	Health Care Organization Accounts Payable To Third Party Payor HealthCareOrganizationAccountsPayableToThirdPartyPayor	4049000	USD
CY2021Q4	us-gaap	Health Care Organization Accounts Payable To Third Party Payor HealthCareOrganizationAccountsPayableToThirdPartyPayor	4240000	USD
CY2022Q1	us-gaap	Interest Payable Current InterestPayableCurrent	4046000	USD
CY2021Q4	us-gaap	Interest Payable Current InterestPayableCurrent	0	USD
CY2022Q1	ati	Accrued Contract Labor Current AccruedContractLaborCurrent	3520000	USD
CY2021Q4	ati	Accrued Contract Labor Current AccruedContractLaborCurrent	2057000	USD
CY2022Q1	ati	Accrued Transaction Related Cost Current AccruedTransactionRelatedCostCurrent	303000	USD
CY2021Q4	ati	Accrued Transaction Related Cost Current AccruedTransactionRelatedCostCurrent	349000	USD
CY2022Q1	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	7396000	USD
CY2021Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	6853000	USD
CY2022Q1	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	59391000	USD
CY2021Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	64584000	USD
CY2022Q1	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	12303000	USD
CY2021Q4	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	1935000	USD
CY2022Q1	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	9880000	USD
CY2021Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	1147000	USD
CY2022Q1	us-gaap	Long Term Debt LongTermDebt	477817000	USD
CY2021Q4	us-gaap	Long Term Debt LongTermDebt	551966000	USD
CY2022Q1	us-gaap	Long Term Debt Current LongTermDebtCurrent	0	USD
CY2021Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	8167000	USD
CY2022Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	477817000	USD
CY2021Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	543799000	USD
CY2022Q1	ati	Proceeds From Issuance Of Temporary Equity And Warrants ProceedsFromIssuanceOfTemporaryEquityAndWarrants	165000000	USD
CY2022Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear	0	USD
CY2022Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	0	USD
CY2022Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	0	USD
CY2022Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	0	USD
CY2022Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	0	USD
CY2022Q1	ati	Long Term Debt Maturity After Year Four LongTermDebtMaturityAfterYearFour	500000000	USD
CY2022Q1	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	500000000	USD
CY2022Q1	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	22183000	USD
CY2022Q1	us-gaap	Long Term Debt LongTermDebt	477817000	USD
CY2022Q1	ati	Proceeds From Issuance Of Temporary Equity And Warrants ProceedsFromIssuanceOfTemporaryEquityAndWarrants	165000000	USD
CY2022Q1	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	200000	shares
CY2022Q1	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	200000	shares
CY2022Q1	ati	Proceeds From Issuance Of Temporary Equity And Warrants ProceedsFromIssuanceOfTemporaryEquityAndWarrants	165000000	USD
CY2022Q1	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	20333000	USD
CY2022Q1	ati	Class Of Warrant Or Right Unamortized Discount ClassOfWarrantOrRightUnamortizedDiscount	203000	USD
CY2022Q1	ati	Class Of Warrant Or Right Issuance Cost ClassOfWarrantOrRightIssuanceCost	405000	USD
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	19725000	USD
CY2021Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2021Q2	ati	Recapitalization Exchange Ratio RecapitalizationExchangeRatio	136.7
CY2022Q1	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	55633000	shares
CY2022Q1	us-gaap	Shares Paid For Tax Withholding For Share Based Compensation SharesPaidForTaxWithholdingForShareBasedCompensation	10000.00	shares
CY2022Q1	us-gaap	Treasury Stock Shares TreasuryStockShares	40000.00	shares
CY2022Q1	us-gaap	Treasury Stock Value TreasuryStockValue	100000	USD
CY2021	ati	Gain Loss On Cash Settlement For Outstanding Preferred Stock GainLossOnCashSettlementForOutstandingPreferredStock	-14000000	USD
CY2022Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	11.50
CY2022Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	11.50
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-23300000	USD
CY2021Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-10500000	USD
CY2022Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.144
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-23300000	USD
CY2021Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.371
CY2021Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-10500000	USD
CY2022Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	16703000	USD
CY2021Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	15823000	USD
CY2022Q1	us-gaap	Variable Lease Cost VariableLeaseCost	5205000	USD
CY2021Q1	us-gaap	Variable Lease Cost VariableLeaseCost	4936000	USD
CY2022Q1	us-gaap	Lease Cost LeaseCost	21908000	USD
CY2021Q1	us-gaap	Lease Cost LeaseCost	20759000	USD
CY2022Q1	ati	Lease Modification Operating Lease Assets Additions LeaseModificationOperatingLeaseAssetsAdditions	5700000	USD
CY2022Q1	ati	Lease Modification Operation Lease Liabilities Additions LeaseModificationOperationLeaseLiabilitiesAdditions	5700000	USD
CY2021Q1	ati	Lease Modification Operating Lease Assets Additions LeaseModificationOperatingLeaseAssetsAdditions	3800000	USD
CY2021Q1	ati	Lease Modification Operation Lease Liabilities Additions LeaseModificationOperationLeaseLiabilitiesAdditions	3800000	USD
CY2022Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	16438000	USD
CY2021Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	16166000	USD
CY2022Q1	ati	Payments For Lease Terminations PaymentsForLeaseTerminations	0	USD
CY2021Q1	ati	Payments For Lease Terminations PaymentsForLeaseTerminations	4570000	USD
CY2022Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	5142000	USD
CY2021Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	5399000	USD
CY2022Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P6Y3M18D
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P6Y4M24D
CY2022Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	6.5
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	6.5
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	50865000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	66781000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	59498000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	50358000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	44009000	USD
CY2022Q1	ati	Lessee Operating Lease Liability Payments Due After Year Four LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour	97574000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	369085000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	70080000	USD
CY2022Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	299005000	USD
CY2022Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	50651000	USD
CY2022Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	248354000	USD
CY2022Q1	us-gaap	Profit Loss ProfitLoss	-138223000	USD
CY2021Q1	us-gaap	Profit Loss ProfitLoss	-17818000	USD
CY2022Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-473000	USD
CY2021Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	1309000	USD
CY2022Q1	ati	Temporary Equity Cumulative Dividend TemporaryEquityCumulativeDividend	1925000	USD
CY2021Q1	ati	Temporary Equity Cumulative Dividend TemporaryEquityCumulativeDividend	0	USD
CY2022Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-139675000	USD
CY2022Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-139675000	USD
CY2021Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-19127000	USD
CY2021Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-19127000	USD
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	199971000	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	199971000	shares
CY2021Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	128286000	shares
CY2021Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	128286000	shares
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.70
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.70
CY2021Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.15
CY2021Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.15
CY2022Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	27544000	shares
CY2021Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	0	shares

Files In Submission

Name	View Source	Status
0001815849-22-000009-index-headers.html	Edgar Link	pending
0001815849-22-000009-index.html	Edgar Link	pending
0001815849-22-000009.txt	Edgar Link	pending
0001815849-22-000009-xbrl.zip	Edgar Link	pending
ati-20220331.htm	Edgar Link	pending
ati-20220331.xsd	Edgar Link	pending
ati-20220331_cal.xml	Edgar Link	unprocessable
ati-20220331_def.xml	Edgar Link	unprocessable
ati-20220331_g1.jpg	Edgar Link	pending
ati-20220331_g2.jpg	Edgar Link	pending
ati-20220331_htm.xml	Edgar Link	completed
ati-20220331_lab.xml	Edgar Link	unprocessable
ati-20220331_pre.xml	Edgar Link	unprocessable
exhibit311_q12022.htm	Edgar Link	pending
exhibit312_q12022.htm	Edgar Link	pending
exhibit32_q12022.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ATIP
ATI Physical Therapy, Inc. Stock $atip

2022 Q2 Form 10-Q Financial Statement

#000181584922000009 Filed on May 10, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ATIP ATI Physical Therapy, Inc. Stock $atip

2022 Q2 Form 10-Q Financial Statement

#000181584922000009 Filed on May 10, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ATIP
ATI Physical Therapy, Inc. Stock $atip